Impella device sales
In the fiscal fourth quarter, Abiomed (ABMD) reported worldwide Impella heart pump sales of ~$168.3 million, which is a year-over-year (or YoY) rise of ~42.0%. The company reported fiscal 2018 Impella heart pump sales of ~$570.9 million, which is a YoY rise of ~35.0%.
In the United States, Abiomed reported Impella heart pump sales of ~$146.2 million in the fiscal fourth quarter, a YoY rise of 35.0%, driven mainly by a 35.0% YoY increase in the usage of these pumps. The company reported fiscal 2018 Impella heart pump sales of ~$505.1 million in the United States, which is a YoY increase of 30.0%. This was driven by a 32.0% YoY rise in the total usage of Impella devices in the United States.
The above chart highlights the utilization mix of Impella devices across indications in the United States in the fiscal fourth quarter. In this quarter, Abiomed witnessed a 26.0% YoY increase in the utilization of Impella devices in the protected percutaneous coronary intervention (or PCI) indication. The YoY rise in emergent usage was around 43.0%.
Impella payer trends
In the 2019 Inpatient Prospective Payment System, released on April 24, the Centers for Medicare and Medicaid Services (or CMS) proposed changing the Diagnosis Related Group (or DRG) code for percutaneous heart pumps, used in catheterization laboratory patients as well as for intensive care unit (or ICU) emergency patients, from the 215 code.
The agency also created a reimbursement code for cases requiring biventricular support with Impella devices. The new reimbursement system is expected to become effective in October after CMS analyzes the data and obtains factual proof of the cost benefits of using Impella devices. To learn more about the payment structure for Impella devices in fiscal 2018, please read Understanding Abiomed’s Changing Payment Structure Plans for Impella.
In the next article, we’ll discuss geographic market expansion trends for Impella.